Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

NRG Oncology190 enrolled

Overview

This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery. Comprehensive patient questionnaires completed before surgery may help identify complications, such as the need for assistance in taking medications, decreased mobility, decreased social activity, and falls, and may improve outcomes for older patients with gynecologic cancer.

PRIMARY OBJECTIVES: I. To determine whether the preoperative geriatric assessment (GA)-gynecology (GYN) score will be associated with major post-operative complications in elderly patients undergoing open primary cytoreduction surgery. SECONDARY OBJECTIVES: I. To explore associations between individual variables of the preoperative geriatric assessment and major post-operative complications in patients undergoing open primary cytoreduction surgery. II. To assess the association between the preoperative GA-GYN score and cytoreducibility defined by extent of residual disease in patients undergoing open primary cytoreduction surgery. TERTIARY OBJECTIVES : I. To evaluate whether the preoperative GA-GYN scores obtained before and after neoadjuvant chemotherapy will be associated with major postoperative complications in elderly patients undergoing open interval cytoreduction surgery. II. To describe reasons why surgeons at centers where open cytoreduction surgery is the standard of care choose to perform interval surgery vs primary surgery, and to explore the association of the preoperative GA-GYN score with the decision to perform primary surgery or interval surgery or no surgery. III. To collect the following specific information on how elderly women with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma are treated at centers that consider open cytoreduction surgery the standard of care: (1) the percentage of patients treated with primary open cytoreduction vs. interval open cytoreduction vs. no surgery and (2) to ascertain the extent of cytoreduction. IV. To determine whether neoadjuvant chemotherapy will be associated with changes in the GA-GYN score to change by comparing the GA-GYN scores obtained before and after neoadjuvant chemotherapy. V. To determine whether 30-day readmission rates after cytoreductive surgery correlate with the GA-GYN score. OUTLINE: At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.

Eligibility

Sex: FEMALEMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma irrespective of performance status; this clinical determination is made by the treating physician * Patients must have signed an approved informed consent and authorization permitting release of personal health information * Patients who can understand sufficiently to be able to respond to questions posed by the study instruments * Patients and/or caregiver (durable power of attorney) can give consent and caregiver can assist with the responses to questionnaire * NOTE: it is the intent of this trial that all patients 70 years or older presenting to the participating physician/center be offered enrollment onto this study; eligible patients may enroll and subsequently receive neoadjuvant chemotherapy followed by interval surgery, primary cytoreductive surgery or no surgery at all * Post-operative pathology will not exclude patients from this study Exclusion Criteria: * Patients whose circumstances at the time of study entry do not permit completion of the study or required follow-up * Patients who would have planned surgery performed by the minimally invasive technique; institutions which perform cytoreductive surgery via the minimally invasive technique should not participate in this study; the minimally invasive surgery (MIS) technique is also not considered standard technique for primary cytoreductive surgery for advanced stage ovarian, fallopian tube or peritoneal cancers * Patients who receive chemotherapy treatment (for a gynecologic malignancy) prior to consideration of enrollment into this trial and taking the geriatric assessment will be excluded * Patients who have a known pre-operative primary uterine cancer, confirmed by endometrial biopsy

Locations (393)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Fairbanks Memorial Hospital

Fairbanks, Alaska, United States

Saint Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

University of Arizona Cancer Center-North Campus

Tucson, Arizona, United States

Kaiser Permanente-Deer Valley Medical Center

Antioch, California, United States

Outcomes

Primary Outcomes

Occurrence of major post-operative complications outlined in The American College of Surgeons' National Surgical Quality Improvement Program

Time frame: Up to 6 weeks after surgery

GA-GYN score, defined as the summation of the risk score for each risk factor derived from the predictive model including 5 risk factors from the GA and 3 other risk factors

Geriatric assessment variables are used in the predictive model; the risk factors will be used to derive the total score.

Time frame: Up to 14 days before surgery

Secondary Outcomes

Extent of residual disease in patients undergoing open primary cytoreduction surgery

The association between the preoperative GA-GYN score and cytoreducibility defined by extent of residual disease in patients undergoing open primary cytoreduction surgery will be assessed. Cytoreducibility is defined as complete cytoreduction (maximum dimension of residual disease =\< 0.1 cm), optimal cytoreduction (maximum dimension of residual disease greater than 0.1 cm but less than or equal to 1.0 cm), or suboptimal cytoreduction (maximum dimension of residual disease greater than 1.0 cm) according to extent of residual disease.

Time frame: 6 weeks after surgery

Functional status, as measured by Instrumental Activities of Daily Living (IADL)

The IADL subscale consists of 7 questions rated on a 3-point Likert scale measuring the degree to which an activity can be performed independently.

Time frame: Up to 14 days before surgery

Functional status, as measured by Activities of Daily Living (ADL)

The ALD uses a subscale of the Medical Outcomes Study physical health with 10 questions rated on a 3-point scale.

Time frame: Up to 14 days before surgery

Patient's overall functioning, as measured by the physician rated performance rating scale

Time frame: Up to 14 days before surgery

Patient's overall functioning, as measured by the self-reported performance rating scale

Time frame: Up to 14 days before surgery

Number of falls in last 6 months

Time frame: Up to 14 days before surgery

Comorbidity, as measured by the Older American Resources and Services (OARS) Physical Health section

The OARS Physical Health Section is a comorbidity scale that contains a list of current illnesses and conditions an individual might have, and the degree to which they impair daily activities, rated on a 3-point scale of " not at all" to " a great deal."

Time frame: Up to 14 days before surgery

Psychological status, as measured by the Mental Health Inventory (MHI) that is based upon the General Well-Being Scale

The full length MHI consists of 38 items grouped into the following five subscales and three global scores: anxiety, depression, general positive affect, emotional ties, and loss of behavioral emotional control, Psychological Distress (negative affect), Psychological Well-Being (positive affect), and the MHI total score a 17 item version of the MHI will be used, which will yield three global scores of Psychological Distress, Psychological Well-Being and MHI total score, as in the original 38 item MHI.

Time frame: Up to 14 days before surgery

Social functioning, as measured by the Medical Outcomes Study (MOS) Social Activity Limitations Measure

The four-item subscale identifies the extent to which physical or emotional problems interfere with an individual's social activities. All items are rated on a 5-point Likert scale, with response categories varying in each item. The mean of the total score is transformed to a scale of 0-100, with a higher number indicating greater support.

Time frame: Up to 14 days before surgery

Social support, as measured by the MOS Social Support Survey

Time frame: Up to 14 days before surgery

Nutritional status, as measured by BMI

Time frame: Up to 14 days before surgery

Nutritional status, as measured by percentage unintentional weight loss in last 6 months

Time frame: Up to 14 days before surgery

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Overview

Conditions

Interventions

Eligibility

Locations (393)

Outcomes

Primary Outcomes

Secondary Outcomes